Aspira Pathlab & Diagnostics Limited has accepted the resignation of Pankaj Jashwant Shah as Managing Director and Chief Executive Director, effective immediately on August 3, 2026. The departure, cited as being due to personal reasons, marks a significant leadership change for the diagnostics firm, which must now navigate the transition without its top executive in place.

The company disclosed the development to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Nikunj Mange, Executive Director of Aspira Pathlab, signed the exchange filing confirming the cessation of Mr. Shah’s tenure.

Resignation Details

Pankaj Jashwant Shah (DIN: 02836324) tendered his resignation from the office of Managing Director and Chief Executive Director. In his resignation letter addressed to the Board of Directors, Mr. Shah stated that he was stepping down due to personal reasons. The resignation becomes effective from the close of business hours on August 3, 2026.

Mr. Shah expressed gratitude to the Board and Management for the opportunity and support extended during his association with the company. He requested the Board to take necessary steps in connection with his resignation as required under applicable laws.

Leadership Transition

The Board of Directors has acknowledged the resignation. As per the disclosure, no relationships between directors were flagged as requiring additional disclosure in this context. The company is expected to inform shareholders about the appointment of a successor or interim arrangements in subsequent filings, though no such details were provided in this specific announcement.

What This Means for Stakeholders

The sudden departure of the Managing Director and Chief Executive Director creates an immediate leadership vacuum at Aspira Pathlab. Investors will be watching for clarity on interim management structures and the timeline for appointing a permanent successor. The absence of a detailed profile or forward-looking statement in the resignation letter suggests the transition may require urgent board-level action to ensure operational continuity.

Aspira Pathlab & Diagnostics Limited has accepted the resignation of Vaibhav Odhekar from the position of Additional Executive Director. The change in leadership is effective from the close of business hours on July 25, 2026, with Odhekar citing personal reasons for his departure.

The company disclosed the development to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Nikunj Mange, Executive Director of Aspira Pathlab, signed the communication on July 25, 2026.

Vaibhav Odhekar, identified by DIN 05135001, submitted his resignation letter to the Board of Directors on July 25, 2026. In his letter, Odhekar expressed gratitude to the Board and management for the support extended during his tenure. He requested the Board to take necessary steps as required under applicable laws.

Resignation Details

The filing confirms that there are no specific disclosures required regarding relationships between directors or other material conflicts related to this resignation. The brief profile section was marked as not applicable in the regulatory annexure.